Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03907488
Title Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Hodgkin's lymphoma, lymphocytic depletion

Hodgkin's lymphoma, nodular sclerosis

Hodgkin's lymphoma

Hodgkin's lymphoma, mixed cellularity

Hodgkin's lymphoma, lymphocytic-histiocytic predominance

Therapies

Pegfilgrastim

Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine

Filgrastim

Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Age Groups: adult | child | senior
Covered Countries USA | CAN


No variant requirements are available.